Irdabisant

ID: irdabisant

Aliases: H3 antagonist/inverse agonist candidate

Type: compound

Route/form: oral or route depends on studied product

Status: investigational_or_research

Evidence level: preclinical

Best data tier: non-human experimental

Support scope: non-human/mechanistic, review/regulatory

Source types: medicinal_chemistry, review

Linked sources: 2

Broad outcomes: Brain / mood / sleep

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• histamine H3 receptor antagonist

Optimization domains

• wakefulness
• cognition
• histamine

Research basis

• H3 antagonism can increase histaminergic and other transmitter release relevant to wakefulness/cognition.
• H3 is a coherent target with multiple development programs.

Limits, risks, and missing evidence

• No direct human trial source is attached; current support should be read as preclinical/mechanistic.
• H3 target promise has not consistently translated to clinical proof across cognition indications.

Risk flags

• CNS
• needs compound identity
• no direct human data found

Linked papers, labels, and reviews

1. Histamine H3 receptor as a target for cognitive disorders
   review / pubmed_h3_cognition_review
   H3 antagonist cognition rationale.
2. Discovery and Characterization of CEP-26401, Irdabisant: A Potent, Selective Histamine H3 Receptor Inverse Agonist
   medicinal_chemistry / acs_irdabisant_cep26401_2011
   Direct medicinal-chemistry characterization of irdabisant/CEP-26401; supports receptor identity and CNS-drug rationale, not clinical efficacy.